Introduction: The differentiated thyroid cancer has generally an excellent prognosis after the treatment. The aim of this study is to describe the characteristics of persistent or recurrent differentiated thyroid cancers. Patients/ Methods: It is about a descriptive and retrospective study conducted from 392 patients followed for differentiated thyroid cancer. The data concerning the persistent or recurrent differentiated thyroid cancer have been collected from 1986 to 2015 in endocrinology service in Ibn Rochd CHU. Results: In total, twenty-four patients have shown the relapse or the persistency of their tumor, corresponding to the prevalence of 6.12 percent. The papillary carcinoma was dominant in 79 percent of cases and the follicular carcinoma in 21 percent of cases. The metastases were cerebral (two cases), lung (3 cases), bones (3 cases, Figure 1), and lymph nodes (9 cases). In our series, eighteen cases of persistent differentiated thyroid cancer have been found against six cases of recurrent differentiated thyroid cancer. Two cases of death at least three years of followed in our series and concerned the two cases of cerebral metastasis. Conclusion: The persistent or recurrent differentiated thyroid cancer rate is low in our series. The discovery of the relapse t is late.
References
[1]
Sapuppo, G., Tavareli, M., Belfiore, A., et al. (2019) Time to Separate Persistent from Recurrent Differentiated Thyroid Cancer: Different Conditions with Different Outcomes. The Journal of Clinical Endocrinology & Metabolism, 104, 258-265.
https://doi.org/10.1210/jc.2018-01383
[2]
Hirsch, D., Levy, S., Tsvetov, G., Gorshtein, A., Slutzky-Shraga, I., Akirov, A., et al. (2017) Long-Term Outcomes and Prognostic Factors in Patients with Differentiated Thyroid Cancer and Distant Metastases. Endocrine Practice, 23, 1193-1200.
https://doi.org/10.4158/EP171924.OR
[3]
Haugen, B.R., Alexander, E.K., Bible, K.C., et al. (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26, 1-133. https://doi.org/10.1089/thy.2015.0020
[4]
Géron, Y., Benbassat, C., Shteinshneider, M., et al. (2019) Long-Term Outcomes after Hemithyroidectomy for Papillary Thyroid Cancer: A Comparative Study and Review of the Literature. Cancers, 11, 26. https://doi.org/10.3390/cancers11010026
[5]
Higashi, T., Nishii, R., Yamada, S., et al. (2011) Delayed Initial Radioactive Iodine Therapy Resulted in Poor Survival in Patients with Metastatic Differentiated Thyroid Carcinoma: A Retrospective Statistical Analysis of 198 Cases. Journal of Nuclear Medicine, 52, 683-689 https://doi.org/10.2967/jnumed.110.081059
[6]
Kim, T.M., Kim, J.H., Yoo, R.E., Kim, S.C., Chung, E.J., Hong, E.K., et al. (2018) Persistent/RECURRENT Differentiated Thyroid Cancer: Clinical and Radiological Characteristics of Persistent Disease and Clinical Recurrence Based on Computed Tomography Analysis. Thyroid, 28, 1490-1499.
https://doi.org/10.1089/thy.2018.0151
[7]
Gomes-Lima, C.J., Wu, D., Rao, S.N., et al. (2019) Brain Metastases from Differentiated Thyroid Carcinoma: Prevalence, Current Therapies and Outcomes. Journal of the Endocrine Society, 3, 359-371. https://doi.org/10.1210/js.2018-00241
[8]
Parker, L.N., Wu, S.Y., Kim, D.D., et al. (1986) Recurrence of Papillary Thyroid Carcinoma Presenting as a Focal Neurologic Deficit. Archives of Internal Medicine, 146, 1985-1987.
[9]
Chiu, A.C., Delpassand, E.S. and Sherman, S.I. (1997) Prognosis and Treatment of Brain Metastases in Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism, 82, 3637-3642. https://doi.org/10.1210/jcem.82.11.4386
[10]
Henriques de Figueiredo, B., Golbert, Y., Soubeyran, I., et al. (2014) Brain Metastases from Thyroid Carcinoma: A Retrospective Study of 21 Patients. Thyroid, 24, 270-276. https://doi.org/10.1089/thy.2013.0061
[11]
Osorio, M., Sami, P., Moubayed, S.P., Su, H. and Urken, M.L. (2017) Systematic Review of Site Distribution of Bone Metastases in Differentiated Thyroid Cancer. Head Neck, 39, 812-818. https://doi.org/10.1002/hed.24655